MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy.
Zinc has a crucial role in the biology of p53 in that p53 binds to DNA through a structurally complex domain stabilized by zinc atom. The p53 negative regulator MDM2 protein also carries a C-terminal RING domain that coordinates two zinc atoms, which are responsible for p53 nuclear export and proteasomal degradation. In this clinically translatable study, we explored the critical role of zinc on p53 reactivation by MDM2 inhibitor, MI-219, in colon and breast cancer cells. ZnCl(2) enhanced MI-219 activity (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), apoptosis and colony formation), and chelation of zinc not only blocked the activity of MI-219, but also suppressed reactivation of the p53 and its downstream effector molecules p21(WAF1) and Bax. N,N,N'N'-tetrakis(-)[2-pyridylmethyl]-ethylenediamine (TPEN), a specific zinc chelator, but not 1,2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (Bapta-AM), a calcium chelator, blocked MI-219-induced apoptosis. Nuclear localization is a prerequisite for proper functioning of p53 and our results confirm that TPEN, and not Bapta-AM, could abrogate p53 nuclear localization and it interfered with p53 transcriptional activation. Addition of zinc suppressed the known p53 feedback MDM2 activation, which could be restored by TPEN. Co-immunoprecipitation studies verified that MI-219-mediated MDM2-p53 disruption could be suppressed by TPEN and restored by zinc. As such, single-agent therapies that target MDM2 inhibition, without supplemental zinc, may not be optimal in certain patients owing to the less recognized mild zinc deficiency among the 'at-risk population' as in the elderly who are more prone to cancers. Therefore, use of supplemental zinc with MI-219 will benefit the overall efficacy of MIs and this potent combination warrants further investigation.
Azmi
A S
AS
Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Philip
P A
PA
Beck
F W J
FW
Wang
Z
Z
Banerjee
S
S
Wang
S
S
Yang
D
D
Sarkar
F H
FH
Mohammad
R M
RM
D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000378:metabolism; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology; D002712:Chlorides / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000378:metabolism; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D045325:HCT116 Cells; D006801:Humans; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D014158:Transcription, Genetic; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D017967:Zinc Compounds / Q000494:pharmacology*
D002614:Chelating Agents; D002712:Chlorides; D004791:Enzyme Inhibitors; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D017967:Zinc Compounds; C016837:zinc chloride; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
Nutrition. 1993 May-Jun;9(3):218-24
8353362
J Biol Chem. 2009 Apr 24;284(17):11517-30
19188367
Science. 1994 Jul 15;265(5170):346-55
8023157
Biochem Biophys Res Commun. 2006 May 26;344(1):272-82
16616005
Genes Dev. 1993 Dec;7(12B):2565-74
8276239
J Lab Clin Med. 2001 Oct;138(4):250-6
11574819
Biochem J. 1993 Dec 1;296 ( Pt 2):403-8
8257431
J Nutr Biochem. 2004 Oct;15(10):572-8
15542347
Mol Carcinog. 1998 Mar;21(3):205-14
9537652
Biochemistry. 2007 Mar 13;46(10):2630-9
17297920
Mol Cell. 2006 Jul 21;23(2):251-63
16857591
Cell. 1997 Feb 7;88(3):323-31
9039259
Nat Rev Cancer. 2009 Dec;9(12):862-73
19935675
Prostate. 2004 Mar 1;58(4):374-81
14968438
Eur J Cancer. 2010 Apr;46(6):1122-31
20156675
Cell Signal. 1998 Mar;10(3):159-66
9607138
Am J Clin Nutr. 1998 Aug;68(2 Suppl):410S-413S
9701153
Cancer Cell. 2007 Oct;12(4):355-66
17936560
Chem Biol. 1994 Nov;1(3):153-61
9383385
Biochemistry. 2003 Mar 4;42(8):2396-403
12600206
J Med Chem. 2006 Jun 15;49(12):3432-5
16759082
Annu Rev Pharmacol Toxicol. 2009;49:223-41
18834305
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10855-60
12145320
Met Ions Biol Syst. 2004;41:103-37
15206115
Trends Mol Med. 2007 Jan;13(1):23-31
17126603
Mol Cancer. 2009 Dec 03;8:115
19958544
Ann N Y Acad Sci. 1995 Sep 30;768:111-28
8526340
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8
18316739
Nutrition. 2001 Jul-Aug;17(7-8):685-7
11448605
Cell Cycle. 2008 Apr 1;7(7):842-7
18414039
J Med Chem. 2009 Dec 24;52(24):7970-3
19928922
Nature. 1997 May 15;387(6630):299-303
9153396
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2776-8
9096291
Toxicol Lett. 2006 Oct 25;166(3):222-8
16930873
J Lab Clin Med. 2002 Oct;140(4):272-89
12389026
Proc Nutr Soc. 1999 Aug;58(3):565-71
10604188
Adv Protein Chem. 1991;42:281-355
1793007
Br J Cancer. 2009 Sep 1;101(5):774-81
19707204
J Am Chem Soc. 2005 Jul 27;127(29):10130-1
16028899
Cell Death Differ. 2010 Jan;17(1):93-102
19498444
Nature. 2004 Feb 26;427(6977):789-90
14985740
Drug Resist Updat. 2003 Dec;6(6):313-22
14744495
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16770-5
12481036
Biochem Pharmacol. 2010 Feb 15;79(4):565-74
19788889
Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):640-5
19684515
Mol Cell Biol. 2007 Feb;27(3):1056-68
17116689
Exp Biol Med (Maywood). 2006 May;231(5):611-8
16636310
Genes Dev. 1993 Dec;7(12B):2556-64
8276238
Mol Cancer Ther. 2008 Sep;7(9):2884-93
18790769
Food Nutr Bull. 2004 Mar;25(1 Suppl 2):S99-203
18046856
Oncogene. 2000 Nov 2;19(46):5227-36
11077439